BioCardia, Inc.
BCDA · XNASCIK 925741fmd_0MP53SRRQYW4J6ZCX0C87Y7681Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Cost of revenue | 1 | 1 | 1 | 0 | 0 | 0 | – | – | – | – |
| Gross profit | (0) | (0) | 0 | 0 | 0 | 1 | – | – | – | – |
| Research and development | 3 | 6 | 8 | 9 | 10 | 9 | 9 | 8 | 4 | 5 |
| Selling, general and administrative | 4 | 6 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | 3 |
| Operating income | (8) | (12) | (14) | (14) | (16) | (13) | (12) | (12) | (8) | (8) |
| Interest expense | 2 | 0 | – | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | – | – | – | – | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | (3) | 0 | 0 | (0) | 1 | 0 | (0) | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (10) | (12) | (14) | (15) | (15) | (13) | (12) | (12) | (8) | (8) |